Naturally Processed Class II Epitope from the Tumor Antigen

نویسندگان

  • Elizabeth M. Hiltbold
  • Pawel Ciborowski
  • Olivera J. Finn
چکیده

Epithelial cell mucin Ml (I is expressed on adenocarcinomas in an underglycosylated form that serves as a tumor antigen in breast, pancre atic, ovarian, and other tumors. Two predominant MUC1-specific im mune responses arc found in patients: CDS* CTLs, which recognize tandemly repeated epitopes on the Miri protein core, and IgM antibod ies. There have been no reports to date of MUCl-specific CD4* T-helper cells in cancer patients. We show here that MUCl-specific CD4+ T cells are neither deleted nor tolerized and that ( 1)4 ' T cell responses can be generated when an appropriate soluble form of Ml (I is used. Naive ( 1)4 ' T cells from healthy donors were primed in vitro to a synthetic MICI peplide of 100 amino acids, representing five unglycosylated tan dem repeats, presented by dendritic cells. They produced II-N-y and had moderate cytolytic activity. We identified one core peptide sequence, PGSTAPPAHGVT. that elicits this response when it is presented by HLA-DR3.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells.

CD4+ T cells play critical roles in initiating, regulating, and maintaining antitumor immune responses. One way to improve current tumor vaccines that mainly induce CTLs would be to activate antigen-specific CD4+ T cells that recognize MHC class II restricted tumor associated antigens. Human telomerase reverse transcriptase (hTRT) is preferentially expressed by various tumors and, therefore, co...

متن کامل

Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3.

The molecular characterization of the CD4(+) T-cell epitope repertoire on human tumor antigens would contribute to both clinical investigation and cancer immunotherapy. In particular, the identification of promiscuous epitopes would be beneficial to a large number of patients with neoplastic diseases regardless of their HLA-DR type. MAGE-3 is a tumor-specific antigen widely expressed in solid a...

متن کامل

Proximity ligation assay evaluates IDH1R132H presentation in gliomas.

For a targeted cancer vaccine to be effective, the antigen of interest needs to be naturally processed and presented on MHC by the target cell or an antigen-presenting cell (APC) in the tumor stroma. The presence of these characteristics is often assumed based on animal models, evaluation of antigen-overexpressing APCs in vitro, or assays of material-consuming immune precipitation from fresh so...

متن کامل

Histocompatibility Complex Class II Alleles Promiscuous MAGE-A3 Epitope Presented by Various Major Tumor-reactive T Helper Lymphocytes Recognize a Updated Version

The development of effective T cell-based immunotherapy for cancer requires the identification of antigens capable of inducing both CTL and T helper immune responses. Although CTLs will participate in the antitumor response mainly by exerting their lytic activity on the tumor cells, helper T lymphocytes will be critical for the induction and maintenance of the CTLs. Thus, effective subunit ther...

متن کامل

Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4.

During immune responses, antigen-presenting cells (APCs) process antigens and present peptide epitopes complexed with human leukocyte antigen (HLA) molecules. CD4 cells recognize these naturally processed and presented epitopes (NPPEs) bound to HLA class II molecules. Epitope identification is important for developing diagnostic and therapeutic tools for immune-mediated diseases and providing i...

متن کامل

Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.

The development of effective T cell-based immunotherapy for cancer requires the identification of antigens capable of inducing both CTL and T helper immune responses. Although CTLs will participate in the antitumor response mainly by exerting their lytic activity on the tumor cells, helper T lymphocytes will be critical for the induction and maintenance of the CTLs. Thus, effective subunit ther...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2006